{
  "name": "Vertex Pharmaceuticals",
  "slug": "vertex-pharmaceuticals",
  "ticker": "VRTX",
  "fetched_at": "2025-08-15T12:22:34.022350+00:00",
  "news": [
    {
      "title": "Stock Analysis | Vertex Pharmaceuticals Outlook - Technicals Favor Growth Despite Mixed Analyst Sentiment - AInvest",
      "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNX3BnX21rekFCQUxfYm9tM3VkV3FNTFVQTHpFRm81Tk5zdUhsQTZMTXFBb1k1RG1XXzNjaGE2SXJLVDhkWTFaT0pndEx1eTJrZlVaZDdOUjZoMVFuRnY4WlNEeVNCNGlZQ2ttdnFRdGZCNVF6blY2d0hXUzJ3OGQxdU12eG8tejVvN2t0YWNCRC1MejdsMkpKejdiQjVGdUM1N2JyemVxRFR5WGYtQkxCaHlMRm5EVk5lcUZULWFEM0VrVnF2bTU0?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMixwFBVV95cUxNX3BnX21rekFCQUxfYm9tM3VkV3FNTFVQTHpFRm81Tk5zdUhsQTZMTXFBb1k1RG1XXzNjaGE2SXJLVDhkWTFaT0pndEx1eTJrZlVaZDdOUjZoMVFuRnY4WlNEeVNCNGlZQ2ttdnFRdGZCNVF6blY2d0hXUzJ3OGQxdU12eG8tejVvN2t0YWNCRC1MejdsMkpKejdiQjVGdUM1N2JyemVxRFR5WGYtQkxCaHlMRm5EVk5lcUZULWFEM0VrVnF2bTU0?oc=5\" target=\"_blank\">Stock Analysis | Vertex Pharmaceuticals Outlook - Technicals Favor Growth Despite Mixed Analyst Sentiment</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>",
      "published": "2025-08-15T03:21:13+00:00",
      "source": "AInvest"
    },
    {
      "title": "Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings May Just Be The Starting Point - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQODBvYnVaZUlPd2FCMWdvTlN1bzk0YkhOdVdUeEdTN1pNOTN0N3hPbnhtazdMSk1zcWswbHRwZGZ5dTc1TGJLaVNVek9hMV9PTl82VkZTSEwzMklhblEyTUFYRXFsQUZhRDFCZ0RZdUx0NE5RaDRHNnREYTFQU2hxdTREMFYxVXB6dFZ1QzlncTJGSVU?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMikwFBVV95cUxQODBvYnVaZUlPd2FCMWdvTlN1bzk0YkhOdVdUeEdTN1pNOTN0N3hPbnhtazdMSk1zcWswbHRwZGZ5dTc1TGJLaVNVek9hMV9PTl82VkZTSEwzMklhblEyTUFYRXFsQUZhRDFCZ0RZdUx0NE5RaDRHNnREYTFQU2hxdTREMFYxVXB6dFZ1QzlncTJGSVU?oc=5\" target=\"_blank\">Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings May Just Be The Starting Point</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-08-12T10:50:42+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "The 3 Things That Matter for Vertex Pharmaceuticals Now - The Motley Fool",
      "link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNWl9vejVmVmZ1bzVtRlBYYUI4X3lwTXhidXU4ZUExQWV0YXRtdXlsaFduSy1xb0dRc1otM0JUUjlTTmhmVERDWnBsVnhVVG53QnRzc3JmZGdQV0RnS1g0cS1lN3ZMRjFncFB1VGZ4bVpWMEw0d3B0bTNQeEVDMjFiVTFyMDY2Q3VDQ3JhVXI3N0FQTnFPLW4xag?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimAFBVV95cUxNWl9vejVmVmZ1bzVtRlBYYUI4X3lwTXhidXU4ZUExQWV0YXRtdXlsaFduSy1xb0dRc1otM0JUUjlTTmhmVERDWnBsVnhVVG53QnRzc3JmZGdQV0RnS1g0cS1lN3ZMRjFncFB1VGZ4bVpWMEw0d3B0bTNQeEVDMjFiVTFyMDY2Q3VDQ3JhVXI3N0FQTnFPLW4xag?oc=5\" target=\"_blank\">The 3 Things That Matter for Vertex Pharmaceuticals Now</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Motley Fool</font>",
      "published": "2025-07-28T07:00:00+00:00",
      "source": "The Motley Fool"
    },
    {
      "title": "Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet (NASDAQ:VRTX) - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNeHYzalNfR1E1cWFrb0Y1SFYxMXQyNnJwV05BcGh3OWk2d21XYzBSYTAtbHZfT25tdFJZRU1uR1lsNXpoeGNENS1mMDZrdmVLRmVZMUZSWmZBOUM0dC1CUU9yOW1vV0J2VWdqbVN4eHotLW90NlF0U3E5TjFIaGVUYVkxakltamVrZjJPQlZ1Nk1PX2gyZUdCOEl3?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimgFBVV95cUxNeHYzalNfR1E1cWFrb0Y1SFYxMXQyNnJwV05BcGh3OWk2d21XYzBSYTAtbHZfT25tdFJZRU1uR1lsNXpoeGNENS1mMDZrdmVLRmVZMUZSWmZBOUM0dC1CUU9yOW1vV0J2VWdqbVN4eHotLW90NlF0U3E5TjFIaGVUYVkxakltamVrZjJPQlZ1Nk1PX2gyZUdCOEl3?oc=5\" target=\"_blank\">Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet (NASDAQ:VRTX)</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-08-12T18:34:19+00:00",
      "source": "Seeking Alpha"
    },
    {
      "title": "Joint Venture Receives $1B Refinancing for Vertex Pharmaceuticals Headquarters Facility in Boston - REBusinessOnline",
      "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOLXhGeTJYbDllQzYya1pOYXVsRDlxREZPbE9IbXJzRFNRT2ZPVzhRczNwYjlTNVZBN25rUFR3c1BJY3VRSlZxZ2JPV0JsdzJNZlVwaWt3aC03eFBDVFJ2bnBIMTBwUnJPWWlBY1lNbUJtZ1VILWxEbWVUZzFKMmxTbi1aUHFZYnBjN3BHeExIVGhWM3lPQjNtWnFrSEJsSUt2YzZVdVhvc0JrUzRGN3g3MGRKdE4wajRxVks0a3NNSmNwWDFq?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMixAFBVV95cUxOLXhGeTJYbDllQzYya1pOYXVsRDlxREZPbE9IbXJzRFNRT2ZPVzhRczNwYjlTNVZBN25rUFR3c1BJY3VRSlZxZ2JPV0JsdzJNZlVwaWt3aC03eFBDVFJ2bnBIMTBwUnJPWWlBY1lNbUJtZ1VILWxEbWVUZzFKMmxTbi1aUHFZYnBjN3BHeExIVGhWM3lPQjNtWnFrSEJsSUt2YzZVdVhvc0JrUzRGN3g3MGRKdE4wajRxVks0a3NNSmNwWDFq?oc=5\" target=\"_blank\">Joint Venture Receives $1B Refinancing for Vertex Pharmaceuticals Headquarters Facility in Boston</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">REBusinessOnline</font>",
      "published": "2025-08-14T11:45:00+00:00",
      "source": "REBusinessOnline"
    },
    {
      "title": "Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat - Investor's Business Daily",
      "link": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPMGFNTjBhUnB5R2tQVzJIZWN2aHlJZ09Rd0VWaThnSWlOd2NKODBHWXo1ZjVVY1o2bzk0aUQtTG5MN0hMNmo4akdyT0tZZ1IwN2ZsQkZSSnJ5cWtMTmRWNGNOSVEydjc4QnZWTmdxR3ZCblhTQ0VEUXFZazdTMndnWmhuU0s2YmdEVHVxNXRFNFRnMi1ROW83MUF3bw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimwFBVV95cUxPMGFNTjBhUnB5R2tQVzJIZWN2aHlJZ09Rd0VWaThnSWlOd2NKODBHWXo1ZjVVY1o2bzk0aUQtTG5MN0hMNmo4akdyT0tZZ1IwN2ZsQkZSSnJ5cWtMTmRWNGNOSVEydjc4QnZWTmdxR3ZCblhTQ0VEUXFZazdTMndnWmhuU0s2YmdEVHVxNXRFNFRnMi1ROW83MUF3bw?oc=5\" target=\"_blank\">Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investor's Business Daily</font>",
      "published": "2025-08-05T07:00:00+00:00",
      "source": "Investor's Business Daily"
    },
    {
      "title": "Vertex's trial failure, scrapped study cloud pain drug push; shares slump - Reuters",
      "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQOEk3LXI4VjBsT0J1aDNCc3BvU3ZZYTgzRlBGOEFuejM3QzFST3lZT3hMUGtNVFFDazVoblY1bUM3bHo2Q1BpOXdCMGx2b0ZvS19qNFl1M3AzUG9zQ1haaWU2Wnk4Y1ZzaEVRRC14RExYMWh3MGM2OWRFekF6NW1yNjhzeXNySFVqc1hhdEdlMjI3ZG4tcnVIdWNGeVI3eU9PSzA5eVdvQVBRNVJETFI5SGtRZDhPWkhxVFllcmp3U3NsZVRfRDRxdGNLbExUS29JcDhkMlV0YTBSQQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQOEk3LXI4VjBsT0J1aDNCc3BvU3ZZYTgzRlBGOEFuejM3QzFST3lZT3hMUGtNVFFDazVoblY1bUM3bHo2Q1BpOXdCMGx2b0ZvS19qNFl1M3AzUG9zQ1haaWU2Wnk4Y1ZzaEVRRC14RExYMWh3MGM2OWRFekF6NW1yNjhzeXNySFVqc1hhdEdlMjI3ZG4tcnVIdWNGeVI3eU9PSzA5eVdvQVBRNVJETFI5SGtRZDhPWkhxVFllcmp3U3NsZVRfRDRxdGNLbExUS29JcDhkMlV0YTBSQQ?oc=5\" target=\"_blank\">Vertex's trial failure, scrapped study cloud pain drug push; shares slump</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Reuters</font>",
      "published": "2025-08-04T07:00:00+00:00",
      "source": "Reuters"
    },
    {
      "title": "Vertex’s Journavx successor culled after falling short in Phase II trial - Clinical Trials Arena",
      "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNTlp6QlZMM09CSTNhd1FHUXZocTc1NnJjbEllbkNjb2VDRlN0dV91Z2ZJUHc3MUt5aUt6TjZ2eVF5bmhGTi1JMVR6a0xVVlpTZmJ0TjZDRUVQRnN5S0F3RDJ5SVY3Q3JTRFdCbUVJelk2MzNkRDVIbExYSjdjN1hmSy1GaGl1dFpFT3hWalZKQjBaOVA4SHZR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMilwFBVV95cUxNTlp6QlZMM09CSTNhd1FHUXZocTc1NnJjbEllbkNjb2VDRlN0dV91Z2ZJUHc3MUt5aUt6TjZ2eVF5bmhGTi1JMVR6a0xVVlpTZmJ0TjZDRUVQRnN5S0F3RDJ5SVY3Q3JTRFdCbUVJelk2MzNkRDVIbExYSjdjN1hmSy1GaGl1dFpFT3hWalZKQjBaOVA4SHZR?oc=5\" target=\"_blank\">Vertex’s Journavx successor culled after falling short in Phase II trial</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Clinical Trials Arena</font>",
      "published": "2025-08-06T09:39:31+00:00",
      "source": "Clinical Trials Arena"
    }
  ],
  "product_launches": [
    {
      "title": "Vertex tops estimates on cystic fibrosis treatment strength, new products - Reuters",
      "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQV1RfcWFhZlB4RnlGTUNfYlJTOEFKaHREZHlEeV9GVHpnaW1zRDliVlMtX3dWdjZkS2RNRWhZaXc0NmdVcW10bVhmQV9NNlh3b3IwckhEME9rTFlIci1hRDF4RlFzRWprOWFTdjlVV1d4dVpIaVFGWXBiWF9tbnJmcFEydUxiNDF1TVJfLTI4QmtvcnIwWVhYd3hNTno2aFhpZF9WNFZjX3lJLVVsNjZfcWZOVTVzU2lXYzV1cmw0bDRpTUFiWjJLUElvRk15d1RKLWJnQy10MmU?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQV1RfcWFhZlB4RnlGTUNfYlJTOEFKaHREZHlEeV9GVHpnaW1zRDliVlMtX3dWdjZkS2RNRWhZaXc0NmdVcW10bVhmQV9NNlh3b3IwckhEME9rTFlIci1hRDF4RlFzRWprOWFTdjlVV1d4dVpIaVFGWXBiWF9tbnJmcFEydUxiNDF1TVJfLTI4QmtvcnIwWVhYd3hNTno2aFhpZF9WNFZjX3lJLVVsNjZfcWZOVTVzU2lXYzV1cmw0bDRpTUFiWjJLUElvRk15d1RKLWJnQy10MmU?oc=5\" target=\"_blank\">Vertex tops estimates on cystic fibrosis treatment strength, new products</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Reuters</font>",
      "published": "2025-08-04T07:00:00+00:00",
      "source": "Reuters"
    },
    {
      "title": "Vertex Reports Second Quarter 2025 Financial Results - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOOExBZmhVaExxYmNrR3k1S1Rlc2MyYkFlQ09oS05WNUtJalFvMmV2Y0hFN294alU0UzF3bGMtOFU1VDZIVUd3aWljbmc5dGN3YWllbndqUDhnQ1l2RWFzSlFVZXlTd2o1TmVhZmtIVFNGb1R0QzNGV2dVZU4xOTVtUXZvaHUyMGs?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihwFBVV95cUxOOExBZmhVaExxYmNrR3k1S1Rlc2MyYkFlQ09oS05WNUtJalFvMmV2Y0hFN294alU0UzF3bGMtOFU1VDZIVUd3aWljbmc5dGN3YWllbndqUDhnQ1l2RWFzSlFVZXlTd2o1TmVhZmtIVFNGb1R0QzNGV2dVZU4xOTVtUXZvaHUyMGs?oc=5\" target=\"_blank\">Vertex Reports Second Quarter 2025 Financial Results</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-08-04T07:00:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "Vertex Pharmaceuticals: Strong Growth and Strategic Advances - TipRanks",
      "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxORGtLZUtKRE5VMFp1WV9YQ3VFU2QySUg0c3pYQjIxNXFDTzlldmw3SGF5emctdmxCWVllTTgyUThPUU1xTkNDRUx2a1ZUTWxUUzg0VVMxd0YzVXJTelFPYk0xdDZHa0pobUJPcVRnenlldm05d2NoTzlPc21vamI5QTVaRTk5UVRDaGRpYm1BbjZPM1h3bWtrMkxueUg0azRQdmwzRi1UMHVsWldERzBQQw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisAFBVV95cUxORGtLZUtKRE5VMFp1WV9YQ3VFU2QySUg0c3pYQjIxNXFDTzlldmw3SGF5emctdmxCWVllTTgyUThPUU1xTkNDRUx2a1ZUTWxUUzg0VVMxd0YzVXJTelFPYk0xdDZHa0pobUJPcVRnenlldm05d2NoTzlPc21vamI5QTVaRTk5UVRDaGRpYm1BbjZPM1h3bWtrMkxueUg0azRQdmwzRi1UMHVsWldERzBQQw?oc=5\" target=\"_blank\">Vertex Pharmaceuticals: Strong Growth and Strategic Advances</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>",
      "published": "2025-08-05T07:00:00+00:00",
      "source": "TipRanks"
    },
    {
      "title": "(suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain - Vertex Pharmaceuticals Newsroom",
      "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQNGhZSnljSUNJSGJ4SzNPVXdNeXNncWRyT1dUWVY2VDVxWDFhamJGQUtSWlhJLVVJMmhSQjROckJNemJGZVlkY3ZmR0ZmYXBiX1J1ZHExdk1ZOW1wTWp5T1ZWa283c2RkYjdkUlgwMEtNejlNb3NJbVZJZlpyVmNweWptQ3dWeDAtV0NfVEJXNG5RU1pTZFRUY01hOEd0SXdwMXFTdEpGTnJTMklMX2NRUnBwUGhndjcyWUJzc0pn?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivgFBVV95cUxQNGhZSnljSUNJSGJ4SzNPVXdNeXNncWRyT1dUWVY2VDVxWDFhamJGQUtSWlhJLVVJMmhSQjROckJNemJGZVlkY3ZmR0ZmYXBiX1J1ZHExdk1ZOW1wTWp5T1ZWa283c2RkYjdkUlgwMEtNejlNb3NJbVZJZlpyVmNweWptQ3dWeDAtV0NfVEJXNG5RU1pTZFRUY01hOEd0SXdwMXFTdEpGTnJTMklMX2NRUnBwUGhndjcyWUJzc0pn?oc=5\" target=\"_blank\">(suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Vertex Pharmaceuticals Newsroom</font>",
      "published": "2025-01-30T08:00:00+00:00",
      "source": "Vertex Pharmaceuticals Newsroom"
    },
    {
      "title": "Vertex Pharmaceuticals' Q2 2025: Unpacking Contradictions in JOURNAVX Strategy, Trial Timelines, and Market Dynamics - AInvest",
      "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcWNEMnctWDJfYzdsYVNWM0RvVFFfSFZieTFPa1Y2YmhJWnVUUmVVMjZ4V0U2bnpXLUtWd28yQVJiU0V2MS1kaldabjFIODFUNnpNcWZwRU9fRXVFUjZXYzhLNEtMZnFaVW10LXhDeGlPT2xQLVJUQmMxRi1ac3lPTlZGV3U3QWN2ZEg3NkRqZW5KcmJ2c2lIZ2NJQzQ1UlhoOFNMblFWbVFxdFVrZmNjNU9faGlxdFpxZDlZbkl3OWFoS0plM2FrajJ3Q25xVkRXLWg5Unpvbw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcWNEMnctWDJfYzdsYVNWM0RvVFFfSFZieTFPa1Y2YmhJWnVUUmVVMjZ4V0U2bnpXLUtWd28yQVJiU0V2MS1kaldabjFIODFUNnpNcWZwRU9fRXVFUjZXYzhLNEtMZnFaVW10LXhDeGlPT2xQLVJUQmMxRi1ac3lPTlZGV3U3QWN2ZEg3NkRqZW5KcmJ2c2lIZ2NJQzQ1UlhoOFNMblFWbVFxdFVrZmNjNU9faGlxdFpxZDlZbkl3OWFoS0plM2FrajJ3Q25xVkRXLWg5Unpvbw?oc=5\" target=\"_blank\">Vertex Pharmaceuticals' Q2 2025: Unpacking Contradictions in JOURNAVX Strategy, Trial Timelines, and Market Dynamics</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>",
      "published": "2025-08-04T07:00:00+00:00",
      "source": "AInvest"
    }
  ],
  "stock": {
    "ticker": "VRTX",
    "currency": "USD",
    "latest": {
      "date": "2025-08-14",
      "close": 390.29998779296875
    },
    "history": [
      {
        "date": "2025-08-06",
        "close": 385.6499938964844
      },
      {
        "date": "2025-08-07",
        "close": 375.6300048828125
      },
      {
        "date": "2025-08-08",
        "close": 366.5400085449219
      },
      {
        "date": "2025-08-11",
        "close": 374.4599914550781
      },
      {
        "date": "2025-08-12",
        "close": 387.7699890136719
      },
      {
        "date": "2025-08-13",
        "close": 395.9200134277344
      },
      {
        "date": "2025-08-14",
        "close": 390.29998779296875
      }
    ],
    "name": "Vertex Pharmaceuticals Incorpor"
  }
}